Sensus Healthcare

Within the dermatology industry, providers are facing a shift in how to handle non-melanoma skin cancers.

For nearly 100 years, the scalpel or Mohs surgery has been the preferred treatment modality for skin cancer.

Innovative technology like superficial radiotherapy (SRT) offers an alternative treatment option with benefits to both patients and providers.

Read more about how innovation continues to impact the dermatology industry in the Medical Product Outsourcing Magazine feature from Sensus Healthcare's President Michael Sardano: https://www.mpo-mag.com/exclusives/from-scalpel-to-srt-impact-of-innovation-on-the-dermatology-industry/

From Scalpel to SRT: Impact of Innovation on the Dermatology Industry SRT technology offers a non-surgical alternative for non-melanoma skin cancer, giving patients an option to manage their care in the way that works best for them.

We’re live at the Veterinary Cancer Society Annual Conference connecting with veterinary oncologists, specialists, and clinicians!

While Superficial Radiotherapy (SRT) has long been an established, non-invasive standard of care for non-melanoma skin cancers and keloids in humans, its role in veterinary medicine is transforming treatment options.

Stop by our booth to meet the team and explore how SRT can offer targeted treatment for animals.

What is Superficial Radiotherapy? The Non-Surgical Choice for Skin Cancer Care:

What is Superficial Radiotherapy? The Non-Surgical Choice for Skin Cancer Care For today’s patients, Superficial Radiotherapy (SRT) serves as an option to treat non-melanoma skin cancer. But, what is it? Learn more in this blog.

"There are now less invasive ways of treating skin cancer, including image guided superficial radiation therapy as well as injectable and topical medications that have been shown to be effective," says Mark Nestor, MD, PhD, director of the Center for Clinical and Cosmetic Research.

Read the full article in Health Leaders, which highlights how innovation continues to expand treatment options for skin cancer: https://www.healthleadersmedia.com/cmo/innovation-expands-treatment-options-skin-cancer

Sensus Healthcare CEO Joe Sardano recently joined the CEO Forum to highlight non-invasive treatment options for non-melanoma skin cancer.

🎙️ Tune in: https://theceoforumgroupinstitute.com/audio/joe-sardano-co-founder-chairman-ceo-sensus-healthcare/

One in five Americans will be diagnosed with skin cancer by the age of 70. There is a growing need for educational information to support patients, caregivers, and anyone who has received a diagnosis.

That's why Sensus Healthcare today announced the launch of its educational platform, Treat Skin Cancer, to provide evidence-based facts and insights.

Read more in our press release: https://sensushealthcare.com/sensus-launches-treat-skin-cancer/

September 11, 2001. 🇺🇸

A day that changed our country forever.

Today, we remember the 2,977 lives taken too soon. We honor the firefighters, police officers, first responders, service members, and ordinary Americans who showed extraordinary courage in the face of unimaginable tragedy.

We remember the families who never got to say goodbye. We remember the heroes who ran toward danger when others were running away. And we remember a nation that, in its darkest hours, came together as one.

25 years later, we still remember.

May we never forget the lives lost, the sacrifices made, and the strength of the American spirit.

United we stood. United we remember. 🇺🇸

Our CEO Joe Sardano joined The Big Biz Show for the seventh time to talk about non-invasive treatment options for non-melanoma skin cancer!

Tune in: https://www.youtube.com/watch?v=MpY-Lt4HefQ

Joe Sardano, co-founder, chairman and CEO of Sensus Healthcare | The Big Biz Show Joe Sardano, co-founder, chairman and CEO of Sensus Healthcare, dis...

Joe Sardano, CEO of Sensus Healthcare (NASDAQ: SRTS) – Big Biz Show The Big Biz Show interviews Sensus Healthcare's CEO Joe Sardano

For decades, surgery has been the go-to standard for treating non-melanoma skin cancer and keloids. But just as modern medicine evolved beyond open bypasses and daily finger pricks, skin care has reached an innovative tipping point.

Learn more about how Superficial Radiotherapy (SRT) is changing treatment pathways for non-melanoma skin cancer:

How 2026 Code Changes Shifted SRT from Sensus Healthcare Code changes and widespread adoption are leading to SRT from Sensus Healthcare to be a standard treatment option for NMSC and keloids.